These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 723476)

  • 1. Allantoxanamide: a potent new uricase inhibitor in vivo.
    Johnson WJ; Chartrand A
    Life Sci; 1978 Nov; 23(22):2239-44. PubMed ID: 723476
    [No Abstract]   [Full Text] [Related]  

  • 2. Uricostatic effect of allopurinol in the allantoxanamide-treated rat: a new method for evaluating antiuricopathic drugs.
    Hropot M; Muschaweck R; Klaus E
    Adv Exp Med Biol; 1984; 165 Pt A():175-8. PubMed ID: 6720375
    [No Abstract]   [Full Text] [Related]  

  • 3. Hyperuricemia and locomotor activity in developing rats.
    Barrera CM; Hunter RE; Dunlap WP
    Pharmacol Biochem Behav; 1989 Jun; 33(2):367-9. PubMed ID: 2813475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allantoxanamide-induced myocardial necrosis in Sprague-Dawley vs spontaneously hypertensive rats.
    Wexler BC
    Proc Soc Exp Biol Med; 1982 Sep; 170(4):476-85. PubMed ID: 7122477
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of fructose administration on serum urate levels in the uricase inhibited rat.
    Stavric B; Johnson WJ; Clayman S; Gadd RE; Chartrand A
    Experientia; 1976 Mar; 32(3):373-4. PubMed ID: 1253916
    [No Abstract]   [Full Text] [Related]  

  • 6. Platelet aggregation in rats made hyperuricaemic with nucleic adid-rich diets containing oxonate, and inhibitor of uricase [proceedings].
    Winocour PD; Munday KA; Taylor TG; Tuner MR
    Proc Nutr Soc; 1976 Sep; 35(2):54A-55A. PubMed ID: 972878
    [No Abstract]   [Full Text] [Related]  

  • 7. Uricase inhibition in the rat by s-triazines: an animal model for hyperuricemia and hyperuricosuria.
    Johnson WJ; Stavric B; Chartrand A
    Proc Soc Exp Biol Med; 1969 May; 131(1):8-12. PubMed ID: 5770131
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of the uricase-inhibited rat as an animal model in toxicology.
    Stavric B; Nera EA
    Clin Toxicol; 1978; 13(1):47-74. PubMed ID: 367691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreasing effect of allantoxanamide, a hyperuricemic agent on renal functions in rats.
    Yonetani Y; Iwaki K; Ogawa Y
    Jpn J Pharmacol; 1987 Sep; 45(1):37-43. PubMed ID: 3119902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raising serum uric acid with a uricase inhibitor worsens PKD in rat and mouse models.
    Chaudhary A; He Z; Atwood DJ; Miyazaki M; Oto OA; Davidoff A; Edelstein CL
    Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1004-F1015. PubMed ID: 38634129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sites of urate transport in the rat nephron.
    Greger R; Lang F; Deetjen P; Knox FG
    Adv Exp Med Biol; 1977; 76B():90-9. PubMed ID: 855767
    [No Abstract]   [Full Text] [Related]  

  • 12. Uric acid kidney stones induced in rats by oxonic acid, a uricase inhibitor.
    Stavric B; Nera EA; Johnson WJ; Salem FA
    Invest Urol; 1973 Jul; 11(1):3-8. PubMed ID: 4724271
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological effects of 1,3,5-triazines and their excretion characteristics in the rat.
    Hropot M; Sörgel F; von Kerékjártó B; Lang HJ; Muschaweck R
    Adv Exp Med Biol; 1980; 122A():269-76. PubMed ID: 6893515
    [No Abstract]   [Full Text] [Related]  

  • 14. Uric acid nephropathy in shocked rats after blocking of uricase activity with triazine compounds.
    Boda D; Pénzes P; Gecse A; Streitman K; Zsilinszky E; Karády I
    Can J Physiol Pharmacol; 1973 Jun; 51(6):496-8. PubMed ID: 4727817
    [No Abstract]   [Full Text] [Related]  

  • 15. Low uricase activity in the Dalmatian dog simulated in mongrels given oxonic acid.
    Yü TF; Gutman AB; Berger L; Kaung C
    Am J Physiol; 1971 Apr; 220(4):973-9. PubMed ID: 5551153
    [No Abstract]   [Full Text] [Related]  

  • 16. Potent competitive uricase inhibitors--2,8-diazahypoxanthine and related compounds.
    Iwata H; Yamamoto I; Goda E; Morita K; Nakamura M
    Biochem Pharmacol; 1973 Sep; 22(18):2237-45. PubMed ID: 4733677
    [No Abstract]   [Full Text] [Related]  

  • 17. Diet-induced hyperuricaemia and platelet aggregation in rats.
    Winocour PD; Munday KA; Taylor TG; Turner MR
    Proc Nutr Soc; 1977 Sep; 36(2):86A. PubMed ID: 905317
    [No Abstract]   [Full Text] [Related]  

  • 18. A preliminary report of nephropathy in hyperuricemic rats.
    Waisman J; Bluestone R; Klinenberg JR
    Lab Invest; 1974 Jun; 30(6):716-22. PubMed ID: 4835598
    [No Abstract]   [Full Text] [Related]  

  • 19. Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors.
    Ishibuchi S; Morimoto H; Oe T; Ikebe T; Inoue H; Fukunari A; Kamezawa M; Yamada I; Naka Y
    Bioorg Med Chem Lett; 2001 Apr; 11(7):879-82. PubMed ID: 11294382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diurnal variation in serum uric acid of rats fed potassium oxonate.
    Newburger J; Combs AB; Hsu TF
    Drug Chem Toxicol; 1978; 1(3):231-5. PubMed ID: 573681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.